Background: High blood pressure is associated with adverse morphological
and functional changes in the cardiovascular system, including left ventricular
hypertrophy (LVH). Osteoprotegerin (OPG) is a member of the tumor necrosis
factor receptor superfamily of cytokines. X-ray repair cross-complementing
protein 3 (XRCC3) is involved in the repair pathway for double-strand breaks
(DSBs). We assessed the association of osteoprotegerin and XRCC3 gene polymorphisms
with the occurrence of left ventricular hypertrophy in hypertensive
patients. Patients and methods: The study included 50 hypertensive patients:
25 with LVH (group A) and 25 without LVH (group B). All cases were
subjected to complete history taking and clinical examination. ECG and
echocardiography were done. LV mass was calculated to detect the presence
or absence of LV hypertrophy. DNA was extracted from blood samples, and
then, each DNA sample was amplified in PCRs, to detect osteoprotogrin and
XRCC3 gene polymorphisms. Results: Mean age in the cases in group A is
63.12 years and in group B was 58.24 years with statistically significant difference
between the two groups. The duration of the disease and SBP revealed
statistically significant difference between the two groups. The LV mass index
and E/A ratio revealed high statistically significant difference between the two
groups. OPG sequence revealed no statistically significant difference between
the two groups, but XRCC3 sequence revealed statistically significant difference.
The age was a risk factor for LVH. Conclusion: Osteoprotogrin and
XRCC3 genes polymorphism mutations may be associated with left ventricular
hypertrophy in hypertensive patients. |
